Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - neisseria meningitidis group a polysaccharide; neisseria meningitidis group c polysaccharide; neisseria meningitidis group w-135 polysaccharide; neisseria meningitidis group y polysaccharide; tetanus toxoid carrier protein - injection, powder, for solution - 5 micrograms - neisseria meningitidis group a polysaccharide 5 micrograms; neisseria meningitidis group c polysaccharide 5 micrograms; neisseria meningitidis group w-135 polysaccharide 5 micrograms; neisseria meningitidis group y polysaccharide 5 micrograms; tetanus toxoid carrier protein ~44 micrograms

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - (mena lyo) meningococcal group a oligosaccharide conjugated to crm197 protein; (mencwy) meningococcal group c oligosaccharide conjugated to crm197 protein; (mencwy) meningococcal group w-135 oligosaccharide conjugated to crm197 protein; (mencwy) meningococcal group y oligosaccharide conjugated to crm197 protein - injection, powder, for solution - 10 microgram conjugated to 16.7-33.3 microgram - (mena lyo) meningococcal group a oligosaccharide conjugated to crm197 protein 10 microgram conjugated to 16.7-33.3 microgram; (mencwy) meningococcal group c oligosaccharide conjugated to crm197 protein 5 microgram conjudated to 7.1-12.5 microgram; (mencwy) meningococcal group w-135 oligosaccharide conjugated to crm197 protein 5 microgram conjugated to 3.3-8.3 microgram; (mencwy) meningococcal group y oligosaccharide conjugated to crm197 protein 5 microgram conjugated to 5.6-10 microgram

European Union - English - EMA (European Medicines Agency)

gsk vaccines s.r.l. - meningococcal group a, c, w-135 and y conjugate vaccine - immunization, meningitis, meningococcal - bacterial vaccines - prefilled syringe menveo is indicated for active immunisation of adolescents (from 11 years of age) and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations. vials menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.,

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - vaccines - nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by neisseria meningitidis group a, c, w-135, and y.

Canada - English - Health Canada

glaxosmithkline inc - meningococcal group a oligosaccharide; meningococcal group c oligosaccharide; meningococcal group w-135 oligosaccharide; meningococcal group y oligosaccharide; corynebacterium diphtheriae crm-197 protein - solution - 10mcg; 5mcg; 5mcg; 5mcg; 47mcg - meningococcal group a oligosaccharide 10mcg; meningococcal group c oligosaccharide 5mcg; meningococcal group w-135 oligosaccharide 5mcg; meningococcal group y oligosaccharide 5mcg; corynebacterium diphtheriae crm-197 protein 47mcg - vaccines

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - neisseria meningitidis group y capsular polysaccharide protein conjugate; neisseria meningitidis group w135 capsular polysaccharide protein conjugate; neisseria meningitidis group a capsular polysaccharide protein conjugate; neisseria meningitidis group c capsular polysaccharide protein conjugate - powder and solvent for solution for injection

European Union - English - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - vaccines - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y.the use of this vaccine should be in accordance with available official recommendations.

Canada - English - Health Canada

sanofi pasteur limited - meningococcal group a polysaccharide-tetanus toxoid conjugate; meningococcal group c polysaccharide-tetanus toxoid conjugate; meningococcal group y polysaccharide-tetanus toxoid conjugate; meningococcal group w polysaccharide-tetanus toxoid conjugate; tetanus toxoid - solution - 10mcg; 10mcg; 10mcg; 10mcg; 55mcg - meningococcal group a polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group c polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group y polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group w polysaccharide-tetanus toxoid conjugate 10mcg; tetanus toxoid 55mcg - vaccines

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - meningococcal polysaccharide, serogroup a (monovalent conjugate); meningococcal polysaccharide, serogroup c (monovalent conjugate); meningococcal polysaccharide, serogroup w-135 (monovalent conjugate); meningococcal polysaccharide, serogroup y (monovalent conjugate); tetanus toxoid, filtered concentrate (carrier protein) - injection, solution - meningococcal polysaccharide, serogroup a (monovalent conjugate) 10 mcg/ 0.5 ml; meningococcal polysaccharide, serogroup c (monovalent conjugate) 10 mcg/ 0.5 ml; meningococcal polysaccharide, serogroup w-135 (monovalent conjugate) 10 mcg / 0.5ml; meningococcal polysaccharide, serogroup y (monovalent conjugate) 10 mcg/ 0.5 ml; tetanus toxoid, filtered concentrate (carrier protein) 55 mcg/ 0.5 ml

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - diphtheria toxoid protein; meningococcal (serogroup a) polysaccharide (monovalent conjugate); meningococcal (serogroup c) polysaccharide (monovalent conjugate); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate); meningococcal (serogroup y) polysaccharide (monovalent conjugate) - injection, solution - 48 microgram (diptheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio) - diphtheria toxoid protein 48 mcg/dose (0.5 ml) (diphtheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio); meningococcal (serogroup a) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup c) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup y) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml)